Masuda, Takeshi
Miura, Satoru
Sato, Yuki
Tachihara, Motoko
Bessho, Akihiro
Nakamura, Atsushi
Miyawaki, Taichi
Yoshimine, Kohei
Mori, Masahide
Shiraishi, Hideaki
Hamai, Kosuke
Haratani, Koji
Maeda, Sumiko
Tabata, Eriko
Kitagawa, Chiyoe
Tanizaki, Junko
Imai, Takumi
Nogami, Shohei
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
Hattori, Noboru
Article History
Received: 13 May 2023
Accepted: 18 October 2023
First Online: 13 November 2023
Competing interests
: Satoru Miura reports personal fees from Chugai Pharmaceutical Co., Ltd.; AstraZeneca K.K; Ono Pharmaceutical Co., Ltd.; Bristol-Myers Squibb; and Takeda Pharmaceutical Co., Ltd. outside the submitted work. Motoko Tachihara reports grants from Chugai Pharmaceutical Co., Ltd. and AstraZeneca K.K. outside the submitted work, in addition to personal fees from Eli Lilly Japan K.K. and Chugai Pharmaceutical Co., Ltd. outside the submitted work. Akihiro Bessho reports grants from Ono Pharmaceutical Co., Ltd.; AstraZeneca K.K.; Pfizer; Chugai Pharmaceutical Co., Ltd.; MSD K.K.; and AbbVie G.K. outside the submitted work. Chiyoe Kitagawa reports grants from Daiichi Sankyo; Sanofi K.K.; Merck Biopharma Co.; and the Public Health Research Foundation outside the submitted work. Junko Tanizaki reports personal fees from AstraZeneca K.K. and Chugai Pharmaceutical Co., Ltd. outside the submitted work. Koji Haratani reports grants from AstraZeneca K.K. Takumi Imai reports lecture fees from Kyowa Kirin Co., Ltd. outside the submitted work. Nobuyuki Yamamoto reports personal fees from MSD K.K.; AstraZeneca K.K.; Amgen Inc.; Ono Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Guardant Health Japan Corp.; Tumura; Kyowa-Kirin Co., Ltd.; Kyorin Pharmaceutical Co., Ltd.; GlaxoSmithKline; Sanofi K.K.; Daiichi-Sankyo Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Nippon Kayaku Co., Ltd.; Boehringer-Ingelheim Co., Ltd.; Novartis; Pfizer Japan Inc.; Bristol Myers Squibb; Miyarisan Pharmaceutical Co., Ltd.; Merck Biopharma Co.; and Janssen Pharmaceutical K.K. outside the submitted work, in addition to grants from Boehringer-Ingelheim Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Shionogi & Co., Ltd.; Eli Lilly Japan K.K.; Daiichi-Sankyo Co., Ltd.; Tumura & Co.; Nippon Kayaku Co., Ltd.; Asahikasei Pharma Corporation; AstraZeneca K.K.; Janssen Pharmaceutical K.K.; Sanofi K.K.; Amgen Inc.; Novartis; Astellas Pharma Inc.; MSD K.K.; Eisai Co., Ltd.; Bristol Myers Squibb; AbbVie G.K; and Tosoh outside the submitted work. Kazuhiko Nakagawa reports personal fees from Eli Lilly Japan K.K.; Chugai Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; and Merck Biopharma Co., Ltd. outside the submitted work, in addition to grants from MSD K.K.; Daiichi Sankyo Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Syneos Health Clinical K.K.; Japan Clinical Research Operations; AstraZeneca K.K.; IQVIA Services JAPAN K.K.; Covance Japan Inc.; Takeda Pharmaceutical Co., Ltd.; GlaxoSmithKline K.K.; Sanofi K.K.; EPS Corporation; Novartis Pharma K.K.; Medical Research Support; Bristol Myers Squibb Company; PRA Health Sciences Inc.; Janssen Pharmaceutical K.K.; Eisai. Inc.; Parexel International Corp.; Ono Pharmaceutical Co., Ltd.; PPD-SNBL K.K; Nippon Boehringer Ingelheim Co., Ltd.; Sysmex Corporation; and Eisai Co., Ltd. outside the submitted work, in addition to scholarship endowments from Takeda Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; and Eisai Co., Ltd. outside the submitted work; he has a patent with Daiichi Sankyo Co., Ltd. outside the submitted work. Noboru Hattori reports personal fees from AstraZeneca K.K. and Boehringer-Ingelheim Japan Inc. outside submitted work and grants from Eli Lilly Japan K.K. and Taiho Pharmaceutical Co., Ltd. outside submitted work. No other disclosures are reported.